Moleculin Biotech financials
$0.5004−4.94%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M | -$19.7M | -$17.5M | -$15.0M | -$8.7M | -$3.9M |
| Net income | -$33.7M | -$26.0M | -$29.8M | -$29.0M | -$15.9M | -$17.4M | -$13.2M | -$11.9M | -$9.8M | -$3.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-28.42 | $-189.14 | $-376.75 | $-5707.50 | $-221.25 | $-660.00 | $-731.25 | $-1035.00 | $-1192.50 | $-900.00 |
| EBITDA | -$25.0M | -$26.5M | -$29.5M | -$30.5M | -$22.8M | -$19.5M | -$17.3M | -$15.0M | -$8.6M | -$3.9M |
| Operating cash flow | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M | -$17.8M | -$17.2M | -$12.2M | -$7.3M | -$3.8M |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M | -$18.1M | -$17.3M | -$12.6M | -$7.4M | -$3.8M |
| Diluted shares | 1.2M | 0.1M | 0.1M | 0.0M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.9M | $4.3M | $23.6M | $43.1M | $70.9M | $15.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M | $29.0M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M | $11.3M |
| Shareholders' equity | $15.0M | $11.2M | $26.1M | $52.2M | $79.0M | $17.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology